However, systemic targeting of two checkpoint inhibitors shown to be highly effective in cancer (that is, anti-PD-1/PD-L1 and anti-CTLA4) accelerated atherosclerosis development in mice49–52 and ischemic heart disease in humans53. Here, PDCD1 is linked to atherosclerosis.